139 related articles for article (PubMed ID: 23326741)
1. Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication.
Socola F; Loaiza-Bonilla A; Benedetto P
Case Rep Oncol Med; 2012; 2012():390702. PubMed ID: 23326741
[TBL] [Abstract][Full Text] [Related]
2. Electrocardiographic manifestations in a large right-sided pneumothorax.
Yamamoto H; Satomi K; Aizawa Y
BMC Pulm Med; 2021 Mar; 21(1):101. PubMed ID: 33757495
[TBL] [Abstract][Full Text] [Related]
3. Promising response to axitinib rechallenge for metastatic renal cell carcinoma after progression on prior axitinib: report of two cases.
Miyake H; Harada KI; Fujisawa M
Int Cancer Conf J; 2018 Jan; 7(1):30-34. PubMed ID: 31149509
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Pleural Empyema with Fistula Caused by Endobronchial Metastasis of Renal Cell Carcinoma].
Kanaki T; Tanaka R; Nakai Y; Yamamoto A; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto K; Nishimura K
Hinyokika Kiyo; 2022 Apr; 68(4):113-116. PubMed ID: 35613899
[TBL] [Abstract][Full Text] [Related]
5. Unusual case of primary spontaneous hemopneumothorax in a young man with atypical tension pneumothorax: a case report.
Chen Y; Guo Z
J Med Case Rep; 2018 Jul; 12(1):188. PubMed ID: 29961427
[TBL] [Abstract][Full Text] [Related]
6. Axitinib for the management of metastatic renal cell carcinoma.
Escudier B; Gore M
Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.
Miyake H; Harada KI; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract][Full Text] [Related]
9. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
11. Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report.
Koie T; Ohyama C; Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y
BMC Res Notes; 2013 Nov; 6():484. PubMed ID: 24267160
[TBL] [Abstract][Full Text] [Related]
12. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
13. [COMPLETE REMISSION OF METASTATIC RENAL CELL CARCINOMA AFTER PARTIAL NEPHRECTOMY FOLLOWING PEMBROLIZUMAB PLUS AXITINIB THERAPY: A CASE REPORT].
Hakamata Y; Uchida K; Noda T; Imai S; Yoneda T; Kudoh S
Nihon Hinyokika Gakkai Zasshi; 2022; 113(4):139-142. PubMed ID: 37866934
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
15. Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.
Rini BI; Tomita Y; Melichar B; Ueda T; Grünwald V; Fishman MN; Uemura H; Oya M; Bair AH; Andrews GI; Rosbrook B; Jonasch E
Clin Genitourin Cancer; 2016 Dec; 14(6):499-503. PubMed ID: 27236772
[TBL] [Abstract][Full Text] [Related]
16. Successful Video-Assisted Thoracoscopic Removal of a Chest Tube Protruding Deep Into the Pulmonary Hilum.
Suzuki M; Horio H; Shimizu R; Shima T; Harada M
Cureus; 2022 Apr; 14(4):e24406. PubMed ID: 35619855
[TBL] [Abstract][Full Text] [Related]
17. Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment.
Takayama K; Numakura K; Igarashi R; Habuchi T
IJU Case Rep; 2022 Nov; 5(6):517-520. PubMed ID: 36341192
[TBL] [Abstract][Full Text] [Related]
18. First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.
Numakura K; Kobayashi M; Muto Y; Sekine Y; Takahashi M; Kashima S; Yamamoto R; Koizumi A; Nara T; Saito M; Narita S; Nanjyo H; Habuchi T
Sci Rep; 2020 Nov; 10(1):20089. PubMed ID: 33208816
[TBL] [Abstract][Full Text] [Related]
19. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
